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Background: Inflammatory bowel diseases (IBD) are chronic diseases of unknown etiology and pathogenesis in
which genetic factors contribute to development of disease. MDR1/ABCB1 is an interesting candidate gene for IBD.
The role of two single nucleotide polymorphisms, C3435T and G2677T remains unclear due to contradictory results
of current studies. Thus, the aims of this research were to investigate the association of MDR1 polymorphisms,
C3435T and G2677T, and IBD.
Methods: A total of 310 IBD patients, 199 Crohn's disease (CD) patients and 109 ulcerative colitis (UC) patients, and
120 healthy controls were included in the study. All subjects were genotyped for G2677T/A and C3435T
polymorphism using RT-PCR. In IBD patients, review of medical records was performed and patients were
phenotyped according to the Montreal classification.
Results: Significantly higher frequency of 2677T allele (p = 0.05; OR 1.46, 95% CI (1.0-2.14)) and of the 3435TT
genotype was observed among UC patients compared to controls (p = 0.02; OR 2.12; 95% CI (1.11-4.03).
Heterozygous carriers for C3435T were significantly less likely to have CD (p = 0.02; OR 0.58, 95% CI (0.36-0.91)).
Haplotype analysis revealed that carriers of 3435T/2677T haplotype had a significantly higher risk of having UC
(p = 0.02; OR 1.55; 95% CI (1.06-2.28)).
Conclusion: MDR1 polymorphisms are associated with both CD and UC with a stronger association with UC.
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Inflammatory bowel disease (IBD) encompasses Crohn's
disease (CD) and ulcerative colitis (UC). Both CD and
UC are chronic inflammatory disorders of the gastro-
intestinal tract with a combined incidence of 2–20 per
100,000 in the developed world [1]. In recent years, con-
siderable progress in the field of IBD genetics has led to
identification of a number of genetic factors involved in
the pathogenesis of the disease. However, the underlying
pathogenesis of IBD remains unclear. It is presumed that
both disorders result as a consequence of defective mu-
cosal barrier and a dysregulated immune response to a* Correspondence: marko.brinar@zg.t-com.hr
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reproduction in any medium, provided the orhost's microbiota in genetically susceptible individual. In
that respect, the multidrug resistance 1 (MDR1) gene,
also known as adenosine triphosphate-binding cassette
superfamily member 1 (ABCB1) is an interesting candi-
date gene for IBD for several reasons. MDR1 encodes a
transmembrane protein, P-glycoprotein 170 (Pgp) which
functions as an ATP-dependent efflux transporter pump
and is highly expressed in the epithelial surfaces of the
intestine, biliary ductules, proximal tubules of kidneys
and central nervous system [2-4]. Although its physio-
logical substrate remains unknown, numerous, structu-
rally different compounds, have been identified as a
substrates of Pgp [5]. In the gut, Pgp is constitutively
expressed on the apical surfaces of the superficial colum-
nar epithelial cells in the intestine with levels of expres-
sion gradually rising from the duodenum to the distaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion in the distal small bowel and colon [6,7]. Although
it physiological function in the gut remains unclear, such
high levels of expression suggest not only a role in pro-
tection against xenobiotics but possibly a role in modu-
lating host-bacterial interactions.
First clue to a possible role od MDR1 in IBD pathogen-
esis comes from a mouse model in which mdr1a knock-
out mice develop colitis resembling ulcerative colitis in a
specific, pathogen free enviroment, that can be alleviated
by a course of antibiotics [8]. Furthermore, MDR1 is
located within a region of suggestive IBD linkage on
chromosome 7q [9]. Finally, MDR1 gene expression is sig-
nificantly reduced in the colonic tissue of UC patientsTable 1 Summary of MDR1 association studies
Author No of cases Tested SNP
Schwab et al. 149 UC C3435T
126 CD
Croucher et al. 307 UC C3435T
562 CD
Brant et al. 119 UC C3435T G2677T
409 CD
Glas et al. 123 UC C3435T
135 CD
Potocnik et al. 144 UC Multiple intron, exon and
promoter polymorphisms
139 CD
Gazzouli et al. 85 UC C3435T
120 CD
Ho et al. 335 UC C3435T
268 CD G2677T
Onnie et al. 580 UC C3435T
828 CD G2677T
Urcelay et al. 330 UC C3435T
321 CD G2677T
Oostenbrug et al. 224 UC C3435T
533 CD
Lal et al. 112 UC C3435T
247 CD
Fiedler et al. 144 UC C3435T
244 CD G2677T
Fischer et al. 149 UC C3435T
265 CD G2677T
Ardizzone et al. 97 UC C3435T
211 CD G2677T
Huebner et al. 401 UC G2677T
483 CD
* Data not in Hardy-Weinberg equilibrium.[10]. These findings combined make MDR1 an excellent
both positional and functional IBD candidate gene.
Two single nucleotide polymorphisms (SNP), namely
the triallelic G2677T/A (rs2032582) in exon 21 and
C3435T (rs1045642) in exon 26, have been shown to cor-
relate with Pgp expression [11-14]. Association of these
SNP's with both CD and UC, either as a single marker or
combined has been extensively studied. However, follow-
ing initial positive associations subsequent studies have
yielded contradictory results [15-30] (Table 1).
In summary, MDR1 is an excellent positional and
functional candidate gene for IBD. However, inconsistent
results of previous studies make its role in IBD controver-
sial. It has to be noted that a vast majority of associationPopulation Results
German T allele associated with UC (p = 0.049)
German & British No association
USA G2677 associated with IBD (p = 0.003)
German No association
Slovenian 2677T associated with UC (p = 0.02); Risk and
protective haplotypes identified for UC and CD
Greece* No association
Scottish 3435T associated with UC (p = 0.02); 3435T
associated with extensive colitis (p = 0.003)
British 2677T associated with UC (p = 0.03)
Spanish* C3435T CC genotype associated with CD
(p = 0.007)
Dutch No association
Canadian 3435T allele associated with CD (p = 0.02)
German No association
Hungarian No association
Italian No association
New Zealand G2677T protective for UC (p = 0.02)
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European populations known to have a higher incidence
of IBD compared to regions of the Southern Europe
suggesting possible genetic differences in these popula-
tions. Therefore, we aimed to investigate the association
between MDR1 G2677T/A and C3435T SNP and
susceptibillity for UC and CD in an independent cohort of
Croatian IBD patients and healthy controls.
Methods
Patients
A total of 199 CD patients and 109 UC patients followed
up for IBD in the University Hospital Centre Zagreb
from 01.01.2006 to 31.12.2010. were included. In all
cases diagnosis of IBD was established according to
standard clinical, radiological, endoscopic and histology
criteria. Patients with unclassified IBD (IBDU) were ex-
cluded from the study. Upon inclusion, clinical records
were reviewed for gender, age at diagnosis, localization
and behavior of disease, extraintestinal manifestations
and need for surgery. Localization and behavior of dis-
ease were defined according to Montreal classification
[31]. The clinical characteristics of patients studied are
summarized in Tables 2 and 3.
A total of 120 age and sex-matched, unrelated, healthy
volunteers recruited from the general population with
no symptoms and no family history of IBD formed aTable 2 Clinical characteristics of CD patients
Number of patients 199
Sex - no. of patients (%)
Female 93 (46.7)
Male 106 (53.3)
Surgery – no of patients (%) 111 (56.3)
Age at diagnosis (years), median
[interquartile range]
25.0 [18.50-31.10]
Age at surgery (years), median
[interquartile range]
28.6 [22.80-36.80]
Disease duration to surgery (years),
median [interquartile range]
3.0 [0.40-6.67]
Localization - no. of patients (%)
Ileal ± UGI 64 (32.2)
Colon ± UGI 34 (17.1)
Ileocolon ± UGI 98 (49.2)
UGI 3 (1.5)
UGI any 29 (14.6)
Behaviour - no. of patients (%)
Inflammatory ± perianal 89 (45.4)
Stricturing ± perianal 65 (33.2)
Penetrating ± perianal 42 (21.4)
Perianal (any) 70 (35.4)control group. All volunteers were questioned regarding
IBD symptoms as well as for symptoms of other immune
mediated diseases such as rheumathologic conditions
and psoriasis. Informed consent was obtained from all
patients and controls prior to inclusion and the study
was approved by the Ethics Committee of the University
Hospital Centre Zagreb.
Genotyping
Genomic DNA was extracted from peripheral lympho-
cytes using the salting out procedure [32]. MDR1 geno-
types of all patients were determined. For the MDR1 exon
21 G2677T/A, and exon 26 C3435T variants, a Real-time
PCR methods were performed using LightCycler (Roche
Applied Sciences, Indianapolis, IN) with the Fast Start
DNA Master plus HybProbe Master Mix [33-35]. To pre-
vent genotyping errors DNA samples were genotyped in
duplicate by RealTime PCR based method. Also every
tenth DNA sample was checked by another method based
on PCR-RFLP.
Statistics
Basic group comparisons were performed using SPSS
17.0.1. (SPSS Inc., Chicago, IL) and Haploview 4.1. Dif-
ferences in continuous variables were tested using the
independent sample t-test and the Mann–Whitney U
test for normally and not normally distributed variables,
respectively.
Allele and genotype frequencies were compared be-
tween groups using the χ2 or Fischer’s exact test when ap-
propriate. Two-sided p values along with odds ratios (OR)
and 95% confidence intervals (CI) were calculated. Haplo-
type frequencies were estimated using the expectation-
maximization (EM) algorithm [36] implemented in
Haploview 4.1. Due to the low frequency of the A allele ofTable 3 Clinical charateristics of UC patients
Number of patients 109
Sex - no. of patients (%)
Female 57 (52.3)
Male 52 (47.7)
Surgery – no of patients (%) 21 (19.8)
Median [interquartile range] age
at diagnosis (yrs)
29.9 [26.0-35.70]
Median [interquartile range] age
at surgery (yrs)
37.3 [31.80-43.10]
Median [interquartile range] disease
duration at surgery (yrs)
4.4 [1.0-7.75]
Localization - no. of patients (%)
Proctitis 11 (10.2)
Left sided colitis 22 (20.4)
Pancolitis 75 (69.4)
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from further analysis. Significance was set at p < 0.05.
Results
Genotype analysis
Genotypes of both C3435T and G2677T/A were in
Hardy-Weinberg equilibrium both in cases and in the
control group. Distribution of allele and genotype fre-
quencies for G2677T/A and C3435T SNP are listed in
Table 4. We observed a trend toward higher frequency
of the T allele of the C3435T SNP in UC patients com-
pared to controls (53.7% vs. 44.6%; p = 0.051). In UC
patients, a significantly higher frequency of the TT geno-
type was observed compared to controls (28.7% vs.
16.0%; p = 0.02; OR 2.12; 95% CI (1.11-4.03)) (Table 4).
Marginally significant difference in the frequency of
2677T allele was observed in UC patients compared to
controls (44.7% vs. 35.2%; p = 0.05; OR 1.46, 95% CI
(1.0-2.14)). No significant differences in genotype fre-
quencies for G2677T SNP were observed in UC cases
compared to controls. No significant differences in allele
frequencies of C3435T and G2677T/A were observed in
CD cases compared to controls. However, association
was detected on genotypic level with heterozygous carriers
for C3435T having a significantly lower risk of having CD
(p = 0.02; OR 0.58, 95% CI (0.36-0.91)). No significant dif-
ferences in genotype frequencies for G2677T SNP were
observed in CD cases compared to controls.
A high degree of linkage disequilibrium was observed
between the two studied SNP's in our sample (D´ = 0.9).
A significant difference in the frequency of carriers of
3435T/2677T haplotype between UC cases and controlsTable 4 MDR1 C3435T and G2677T allele and genotype frequ
Controls (n = 120) CD (n
C3435T
Allele frequencies (%)
Allele C 132 (55.5) 208 (52
Allele T 106 (44.5) 188 (47
Genotype frequencies (%)
CC 32 (26.9) 61 (30.
CT 68 (57.1) 86 (43.
TT 19 (16.0) 51 (25.
G2677T/A
Allele frequencies (%)
Allele G 149 (64.2) 239 (61
Allele T 83 (35.8) 149 (38
Genotype frequencies (%)
GG 47 (40.5) 82 (42.
GT 55 (47.4) 75 (38.
TT 14 (12.1) 37 (19.was observed with carriers of that haplotype having a
significantly higher risk of having UC (p = 0.02; OR 1.55;
95% CI (1.06-2.28)) (Table 5). No significant differences
in 2-locus haplotype frequencies were observed in CD
cases compared to controls.
Discussion
In this study, we investigated the association of MDR1
polymorphisms and IBD in a cohort of well charaterized
patients. We detected a significant association of C3435T
and G2677T polymorphism and UC with higher fre-
quency of mutant allele and/or genotype carriers in the
UC patient group. In that respect, our results are in
accordance with previously published results reporting the
association of UC with G2677T and C3435T SNP
[15,17,20,21,23]. Contrary to the previously published re-
sults, we detected no association of C3435T variant with
pancolitis although a large proportion of our UC patient
group had pancolitis (69.4%) [21]. Furthermore, due to the
high LD between the two studied SNP's, we were able to
investigate the association with two-locus haplotypes. Pre-
vious studies reported both risk and protective haplotypes
in the same cohort suggesting a complex influence of
MDR1 in pathogenesis of disease [20,21]. We detected a
significantly higher frequency of 3435T/2677T haplotype
carriers in the UC patient group. The same haplotype is
also a part of two haplotypes associated with UC in the
study by Potocnik et al. performed on Slovenian IBD
patients [20].
We found no significant difference in allele distributions
of investigated SNP's between CD patient group and con-
trols. However, we detected a significant association ofencies in CD, UC and control group
= 199) p value UC (n = 109) p value
.5) 0.47 100 (46.3) 0.051
.5) 116 (53.7)
8) 0.52 23 (21.3) 0.35
4) 0.02 54 (50.0) 0.29
8) 0.05 31 (28.7) 0.02
.6) 0.51 119 (55.1) 0.05
.4) 97 (44.9)
3) 0.72 33 (30.5) 0.16
6) 0.16 53 (49.1) 0.69
1) 0.11 22 (20.4) 0.10
Table 5 Frequencies of two-locus MDR1 haplotypes in CD
and UC cases and controls
Haplotype Controls (%) UC (n%) p value CD (%) p value
C3435/G2677 126 (53.4) 97 (44.6) 0.07 202 (51.0) 0.62
3435T/2677T 78 (33.1) 94 (43.2) 0.02 145 (36.6) 0.34
3435T/G2677 28 (11.9) 23 (10.5) 0.69 43 (10.9) 0.765
C3435/2677T 6 (2.6) 4 (1.7) 0.56 6 (1.5) 0.405
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genotype were significantly less represented in the CD pa-
tient group suggesting a protective effect. How exactly a
heterozygous state confers protection is hard to explain at
this moment. However, the same genotype was also found
to be protective in UC in the study by Huebner et al. [30].
In this study the investigators put forward an interesting
hypothesis that heterozygous carriers of certain MDR1
variants are more resistant to certain bacterial infections
[30]. This hypothesis is based on the data from other
diseases, like cystic fibrosis or sickle cell anemia, where
heterozygous advantage exists [30]. However, although ap-
pealing, this hypothesis still needs to be tested, especially
on a functional level.
The G2677T polymorphism is a coding polymorphism
resulting in substitution of alanine by serine in the Pgp
amino acid sequence. Studies investigating the influence
of this polymorphism on Pgp expression have reached
conflicting results with Kim et al. reporting association
of 2677T allele with higher levels of Pgp expression [14].
However, Kimchi-Sarfaty et al. reported no influence of
this polymorphism on expression level and intracellular
localisation of Pgp [37]. However, G2677T polymorph-
ism might exert its effect not by influencing levels of ex-
pression of Pgp but by altering Pgp stability or affinity
for a certain substrate. On the other hand, C3435T has
been associated with low levels of Pgp expression in
Caucasians [11]. Interestingly, the opposite was found in
Japanese subjects emphasizing the interethnical diffe-
rences in Pgp expression [12]. The association of
C3435T with low levels of Pgp expression in caucasians
is in concordance with data from animal models with
mdr1−/− developing colitis. Interestingly, C3435T is a
synonymous SNP not leading to change in amino acid
sequence. The possible explanation of the association of
a synonymous SNP with altered levels of Pgp expression
was offered by finding of moderate reduction of Pgp
mRNA stability associated with this SNP [38]. Another
possible explanation lies in the high levels of linkage dis-
equilibrium within the MDR1 gene with C3435T in link-
age with the true causal variant [5].
In general, our results seem to be in accordance with
some of the previously published studies [15,17,20,21,23].
However, in a multitude of studies no association ofinvestigated SNP's and UC was found [16,18,19,22,
25,27,29]. The reason for such variability of results in the
literature is not clear, however population heterogeneity
seems to be the most plausible explanation. In the pub-
lished studies frequency of the 3435T allele varied from
41%-65.3% in the UC patient group while frequency of
2677T allele varied from 40%-53% [15-30]. Even greater
variation of mutant allele frequency can be found in the
respective control groups where 3435T allele frequency
varied from 37%-63% and 2677T allele frequency varied
from 40%-53% [15-30]. The importance of the mutant
allele frequency is further emphasized by study by Glas
et al. in which the investigators used two separate controls
groups. Performing the association analysis with control
group 1 that had a 3435T allele frequency of 52.8% no sig-
nificant association of the 3435T allele and UC was found.
However, when control group 2 was used for analysis with
3435T allele frequency of 43.7 a significant association of
3435T allele and UC was found [18]. Due to the fact that
the differences in the minor allele frequencies between the
IBD group and the control group are quite modest it is
quite possible that differences in the minor allele frequen-
cies of the tested SNP's in the controls groups account for
the majority of different results in the literature regarding
these two SNP's. Importantly, the frequency of 2677T al-
lele in our control group was 35.8% which represents the
lowest frequency published to date in a European popula-
tion. Interestingly, the frequency of 2677T allele, in the
ethnically similar, Slovenian control group in the study by
Potocnik et al. was also among the lowest reported in the
literature (40%) [20]. Our study further emphasizes diffe-
rences between various European populations and under-
scores the importance of replication of results of genetic
studies in different ethnic groups.
Finally, our study had several weaknesses. IBD patients
included in the study represent the IBD population of a
tertiary refferal center. As a consequence, majority of pa-
tients have extensive disease, especially in the UC group.
Therefore, we can not exclude the possibility of bias
since our cohort does not include a large number of pa-
tients with limited disease of low activity. Furthermore,
although we detected a significant association of tested
SNP's with UC and CD, the magnitude of the effect is
modest. Given our relatively small sample size, our study
had only 43% power to detect the effect of this magni-
tude. Taking this into account, the results of our study,
although generally in accordance with previous reports,
must be interpreted with caution.
Conclusion
In conclusion, our results confirm the role of MDR1 in
both CD and especially in UC pathogenesis although the
overall influence of MDR1 variants on disease suscepti-
bility is modest.
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